Physician profile
Jane Kim
NPI 1306947171
$4,975.76
in general payments reported to CMS, 2019-2025
27 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $86.33 · 2021: $450 · 2022: $901 · 2023: $997 · 2024: $1,146 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,057.92 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,497.12 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $499.31 | 2019-2025 | |
| Dermavant Sciences, INC. | $434.42 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $288.96 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $209.31 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $207.71 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $186.08 | 2021-2025 | |
| Pfizer INC. | $182.93 | 2019-2025 | |
| Amgen INC. | $142.22 | 2023-2025 | Otezla, Otezla |
| Leo Pharma INC. | $139.73 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $137.37 | 2019-2024 | Libtayo |
| Lilly USA, LLC | $128.75 | 2022-2025 | Olumiant, Ebglyss, Taltz |
| Organogenesis INC. | $127.83 | 2024-2025 | Affinity, Apligraf |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.61 | 2019-2021 | |
| Incyte Corporation | $113.75 | 2021-2025 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $105.92 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $76.82 | 2020-2025 | Aklief, Nemluvio |
| Mayne Pharma Commercial LLC | $64.98 | 2022-2025 | |
| Journey Medical Corporation | $64.60 | 2023-2025 | |
| Almirall LLC | $53.86 | 2021-2022 | |
| Organon LLC | $53.27 | 2025 | Vtama |
| Botanix Sb INC | $37.59 | 2025 | Sofdra |
| Genzyme Corporation | $30.53 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.69 | 2022 | |
| Aclaris Therapeutics, INC. | $17.97 | 2019 | |
| Verrica Pharmaceuticals INC. | $16.45 | 2023 | Ycanth |
| Biofrontera INC. | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.